Kenneth Mills compensation by year
REGENXBIO Summary Compensation Table · all 9 fiscal years held| Component | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|
| Salary | $514,890 | $530,450 | $546,364 | $595,537 | $613,403 | $631,805 | $650,759 | $676,790 | $340,998 |
| Bonus | $0 | $0 | $0 | $0 | $0 | $600,000 | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $0 | $0 | $0 | $1,843,050 | $1,228,161 | $1,218,254 | $1,175,649 |
| Option awards | $1,979,413 | $1,734,200 | $3,895,222 | $5,160,444 | $6,646,254 | $5,057,556 | $3,505,846 | $3,698,138 | $3,489,594 |
| Non-equity incentive | $206,000 | $278,486 | $480,800 | $375,188 | $368,042 | $473,854 | $351,410 | $304,555 | $406,074 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $17,706 | $15,525 | $15,813 | $16,100 | $16,388 | $16,675 | $17,538 | $18,975 | $94,723 |
| Total | $2,718,009 | $2,558,661 | $4,938,199 | $6,147,269 | $7,644,087 | $8,622,941 | $5,753,713 | $5,916,713 | $5,507,038 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: REGENXBIO Inc. DEF 14A filed April 8, 2025, accession 0000950170-25-052069, and prior-year filings. Open the filing on EDGAR.
How this page was built: the REGENXBIO Inc. filed document, accession 0000950170-25-052069. Every figure is read from that document and cited to the page and table it appears in. Filed April 8, 2025.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 64,103 | $495,516 | — |
| RSU | 41,065 | $317,432 | — |
| RSU | 17,898 | $138,352 | — |
| RSU | 10,246 | $79,202 | — |
| Option | 3,858 | — | $44.97 |
| Option | 305,250 | — | $18.34 |
| Option | 46,093 | — | $34.31 |
| Option | 137,985 | — | $22.25 |
Per the Outstanding Equity Awards at Fiscal Year-End table in REGENXBIO Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
10 Form 4 lines since the FY2024 proxy (filed April 8, 2025)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-05-29 | Grant or award | — | 9,807 | $0.00 | 495,925 |
| 2026-05-29 | Grant or award derivative | — | 46,600 | $0.00 | 46,600 |
| 2026-01-27 | Exercise or conversion derivative | — | 225,000 | $0.00 | 225,000 |
| 2026-01-27 | Tax withholding | — | 221,753 | $13.41 | 486,118 |
| 2026-01-27 | Exercise or conversion | — | 225,000 | $13.09 | 707,871 |
| 2025-05-30 | Grant or award | — | 7,768 | $0.00 | 482,871 |
| 2025-05-30 | Grant or award derivative | — | 39,815 | $0.00 | 39,815 |
| 2025-05-12 | Exercise or conversion | 10b5-1 | 20,602 | $3.76 | 495,705 |
The 8 most recent of 10 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
REGENXBIO’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Kenneth Mills · this page | Former President and CEO | $5,507,038 |
| Curran Simpson | President and Chief Executive Officer | $4,784,543 |
| Mitchell Chan | EVP, Chief Financial Officer | $3,205,294 |
| Olivier Danos | EVP, Chief Scientific Officer | $2,956,949 |
| Patrick Christmas | EVP, Chief Strategy and Legal Officer | $2,737,813 |
| Stephen Pakola | EVP, Chief Medical Officer | $2,696,858 |
| Vit Vasista | Former EVP, Chief Financial Officer | $2,226,951 |
Board service
REGENXBIO board · FY2021–FY2025| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $80,000 | $68,747 | $206,247 | $0 | $354,994 |
| FY2024 | $40,000 | $0 | $0 | — | $40,000 |
| FY2023 | — | — | — | — | — |
| FY2022 | — | — | — | — | — |
| FY2021 | — | — | — | — | — |
Each year as the company reported it in REGENXBIO's director compensation table. Totals are the company's own disclosed totals.
How this board is paid
Company policy: REGENXBIO pays directors a $45,000 cash retainer and $275,000 in Options and RSUs. As stated in REGENXBIO's FY2025 proxy.
The full REGENXBIO compensation record
free company briefThis page is one person within REGENXBIO's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the REGENXBIO proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are REGENXBIO's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.